Benjamin Halevy Rosenstein, Vice President of Reasearch and Development at Pharmocann, an Israeli medical cannabis company, speaks during his interview with Reuters, at the company’s hothouse in northern Israel January 24, 2019. REUTERS/Amir Cohen